Biohaven Pharmaceutical Hld

Biohaven Ltd. operates as a biopharmaceutical company that focuses on neurological and neuropsychiatric diseases. Its portfolio includes treatments for medical needs including focal epilepsy, obsessive compulsive disorder, spinocerebellar ataxia and spinal muscular atrophy. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Coty

Danaher

Foot Locker

Biglari Hlds

Stoke Therapeutics Inc

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there was before and after the elections and as the pandemic worsens.

Notable Insider Buys in the Past Week: Biglari, Coty, Danaher, Foot Locker And More

"I hope that in six months or so from now that we will be the first oral CGRP with the indication for the prevention of migraine," Biohaven CEO Vlad Coric said.

Biohaven eyes mid-2021 for migraine prevention drug launch

NEW HAVEN, Conn., Nov. 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced that Dr. Richard Granstein, M.D., Chairman of Dermatology...

Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis

NEW HAVEN, Conn., Nov. 11, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and...

Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) CEO Vlad Coric on Q3 2020 Results - Earnings Call Transcript

  Shares of Biohaven Pharmaceutical (NYSE:BHVN) traded flat in pre-market trading after the company reported Q3 results.

Recap: Biohaven Pharmaceutical Q3 Earnings

ACADIA Pharma

Alnylam Pharmaceuticals

AvroBio Inc

BioNTech SE

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates

NEW HAVEN, Conn., Oct. 30, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its...

Biohaven To Report Third Quarter 2020 Financial Results And Recent Business Developments On November 9, 2020

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting 30,000 to generate strong returns. However, as we know, big investors usually buy stocks with strong fundamentals that can deliver gains both in bull and bear markets, which is why we believe we can profit from imitating them. In this article, we are going to take a look at the smart money sentiment surrounding Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN).

Were Hedge Funds Right About Biohaven Pharma (BHVN)?

Biohaven (BHVN) is seeking the label expansion of its migraine drug Nurtec ODT as a preventive treatment of migraine.

FDA Accepts Biohaven's (BHVN) sNDA for Migraine Drug Nurtec

NEW HAVEN, Conn., Oct. 14, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review its recently submitted supplemental New Drug Application (sNDA) for NURTEC™ ODT...

U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC™ ODT For The Preventive Treatment Of Migraine

NEW HAVEN, Conn., Sept. 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing

A Relative Strength Rating upgrade for BiohavenPharmaHldg shows improving technical performance.

BiohavenPharmaHldg Reaches 80-Plus Relative Strength Rating Benchmark

Biohaven Is Still A Bargain On Increasing Nurtec ODT Sales

Biohaven Pharmaceutical Holding Company Ltd (BHVN) CEO Vladimir Coric on Q2 2020 Results - Earnings Call Transcript

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, demonstrates strong launch uptake.

Biohaven (BHVN) Q2 Earnings Beat on Strong Nurtec Uptake

NEW HAVEN, Conn., Aug. 10, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments

NEW HAVEN, Conn., Aug. 7, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Announces up to $500 Million Non-Dilutive Term Loan with Sixth Street

Royalty Pharma

Biohaven will receive up to $250 million to fund zavegepant's development in migraine and non-migraine indications

Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million

NEW HAVEN, Conn., Aug. 3, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General Hospital

NEW HAVEN, Conn., July 21, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy

Biohaven Pharmaceutical Holding Co. Ltd.'s (NYSE: BHVN) "Nurtec ODT" drug will be promoted by media personality Khloe Kardashian, the company announced Wednesday.

Biohaven Pharmaceutical's Migraine Drug To Be Promoted by Khloe Kardashian

Khloe Kardashian is working with Biohaven Pharmaceuticals to promote its newly launched migraine drug, Nurtec ODT.

Biohaven Pharmaceuticals lands Khloe Kardashian as influencer of new migraine drug

Biohaven Pharmaceutical delivered mixed results for its OCD treatment test on Wednesday — leading BHVN stock to tumble. Biohaven studied a drug called troriluzole in OCD patients.

News for Biohaven Pharmaceutical Hld Stock (BHVN)